<DOC>
	<DOCNO>NCT00331253</DOCNO>
	<brief_summary>To establish safety efficacy indocyanine green-mediated photothrombosis ( i-MP ) treatment patient neovascular age-related macular degeneration .</brief_summary>
	<brief_title>Treatment Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis ( i-MP ) .</brief_title>
	<detailed_description>Comparative , control , multicenter , mask , randomize study , three parallel group , compare Indocyanine Green-Mediated Photothrombosis two control group , treatment neovascular Age-Related Macular Degeneration . Only patient match follow criterion eligible : A. BCVA worse 20/80 neovascular complex component occult CNV define fluorescein angiography , ; B. BCVA worse 20/80 neovascular complex total area CNV ( classic occult ) fluorescein angiography occupy area lesser 50 % neovascular complex , ; C. BCVA worse 20/200 neovascular complex CNV ( classic OR occult ) fluorescein angiography . The eligibility patient assess independent Centre Interpretation mask analysis . Eligible patient allocate one three study group , randomize 2:1:1 proportion : Group 1 : Treatment Procedure # 1 = i-MP ( ICG + Laser ) , proportion 2 . In group patient submit endovenous infusion ICG follow irradiation diode laser . Group 2 : Treatment Procedure # 2 ( Distilled water + Laser ) , proportion 1 . In group patient receive endovenous placebo infusion ( distilled water ) follow irradiation diode laser power utilized Group 1 . Group 3 : Treatment Procedure # 3 ( Distilled water + Sham Laser ) , proportion 1 . In group patient receive endovenous placebo infusion ( distilled water ) follow simulated application laser .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Age 50 year ; Presence least 1 soft drusen macular region , associate pigment alteration ( hyper hypopigmentation ) , thus characterise AMD ; Reduction vision due exclusively macular exudative process result formation associate choroidal neovascularisation ( neovascular AMD ) ; Patients present : Neovascular complex characterise presence occult CNV component formation fluorescein angiography BCVA bad 20/80 , OR ; Neovascular complex total CNV ( classic occult ) area fluorescein angiography occupy area lesser 50 % neovascular complex BCVA worse 20/80 , OR ; BCVA lesser 20/200 , regardless type composition neovascular complex ; Direct involvement avascular foveal zone neovascular complex ; Informed Consent Form write appropriately sign . BCVA lesser 20/400 ; Greatest linear dimension neovascular complex great 6000 ( six thousand ) micron ; Previous Photodynamic Therapy ( PDT ) ; Thermal laser treatment CNV ; Intra vitreous injection corticosteroid antiangiogenic drug ; Opacities medium significantly interfere VA , clinical ophthalmic assessment , documentation eye fundus performance laser therapy ; Other cause CNV pathologic myopia ( spherical equivalent great 6 [ six ] spherical diopter and/or axial length great 26mm ) , angioid streak , active uveitis , ocular presume histoplasmosis traumatic choroidal rupture ; CNV associate serous/sero hemorrhagic RPED ( vascular RPED / hemorrhagic RPED ) ; Absence identifiable CNV fluorescein angiography ( massive presence thick blood ) ; CNV absence ICG uptake ICG angiography despite eligibility patient clinical criterion fluorescein angiography ; Intraocular surgery undertaken last 3 month ; Posterior vitrectomy retinopexy scleral introflexion , time ; Severe form nonproliferative Diabetic Retinopathy ; Acute ocular infection ; Ionizing radiation treatment face , skull neck region ; Allergy fluorescein indocyanine green ; Excessive know use alcohol drug ; Medical psychological condition may impede patient complete study sing Informed Consent Form ; Significant uncontrolled disease , opinion investigator , may exclude patient study ; Impediment limit legal capability ; Participation clinical study last 30 day . NOTE : Patients participate clinical study last 12 month , even though finish participation prior last 30 day , eligible inclusion participation present protocol bring clear benefit patient .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Indocyanine Green-Mediated Photothrombosis</keyword>
	<keyword>Neovascular</keyword>
	<keyword>Age-Related Macular Degeneration</keyword>
</DOC>